Cetera Advisor Networks’s Niagen Bioscience NAGE Stock Holding History

Cetera Advisor Networks’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25,000	Closed	-$82K	–	3469
2020 Q1	$82K	Hold	25,000	–	–	﹤0.01%	1073
2019 Q4	$108K	Hold	25,000	–	–	﹤0.01%	1205
2019 Q3	$98K	Hold	25,000	–	–	﹤0.01%	1155
2019 Q2	$116K	Hold	25,000	–	–	﹤0.01%	1138
2019 Q1	$105K	Hold	25,000	–	–	﹤0.01%	1109
2018 Q4	$86K	Hold	25,000	–	–	﹤0.01%	1005
2018 Q3	$107K	Hold	25,000	–	–	﹤0.01%	1101
2018 Q2	$93K	Hold	25,000	–	–	﹤0.01%	823
2018 Q1	$105K	Hold	25,000	–	–	﹤0.01%	830
2017 Q4	$147K	Buy	+25,000	New	+$135K	0.01%	945

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sycale Advisors New York $201M AUM 2.35% 1-Year Est. Return

Cetera Advisor Networks's NAGE Position: Q2 2020 in Review

Cetera Advisor Networks sold out of Niagen Bioscience (NAGE) in Q2 2020, closing a stake of 25,000 shares — an estimated $82K sold.

Cetera Advisor Networks first reported a position in NAGE in Q4 2017 and held it in 10 quarters. The position peaked at $147K in Q4 2017. 66 funds tracked by Wall St. Rank hold NAGE as of Q2 2020.

Cetera Advisor Networks reported no remaining Niagen Bioscience position as of Q2 2020 after selling out during the quarter.
Cetera Advisor Networks sold 25,000 Niagen Bioscience shares in Q2 2020, an estimated $82K.
Cetera Advisor Networks first reported a position in Niagen Bioscience in Q4 2017 and held it in 10 quarters.
Cetera Advisor Networks's Niagen Bioscience position peaked at $147K in Q4 2017.
66 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2020.

Based on Cetera Advisor Networks's 13F filing for Q2 2020, filed 13 Aug 2020.